Author Archives: Patricia Silva, PhD

Throughout 2015, Mitochondrial Disease News reported on studies into therapies, insights into the mechanisms underlying mitochondrial diseases, and related events. As the year comes to an end, here are the 10 articles most viewed by Mitochondrial Disease News readers, each with a brief summary of the developments that made them of such…

NuSirt Biopharma, a company focused on therapies for chronic metabolic diseases, recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s development program to treat non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). Mitochondrial dysfunction in the liver plays a key…

ChromaDex Corp., a company dedicated to technologies in wellness, health, dietary/nutrition supplements, skin care and pharmaceuticals, recently announced a Materials Cooperative Research and Development Agreement (MCRADA) over the company’s product NIAGEN with the National Institute on Aging (NIA), part of the National Institutes of Health (NIH). NIAGEN is…

A study recently published in the journal Cell Reports revealed the mechanism by which a benign kidney tumor can develop into an aggressive cancer, and the role mitochondria dysfunction has on this process. The study, titled “The Genomic Landscape of Renal Oncocytoma Identifies a…

A new study published in the journal Cell Metabolism revealed that exercise can energize brain cell function in animal models by increasing the levels of a specific mitochondrial enzyme. The finding may have important therapeutic implications for the treatment of age-related cognitive decline and neurodegenerative diseases. The study…

Viking Therapeutics, Inc., a biopharmaceutical company specializing in therapies for endocrine and metabolic conditions, recently announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for its drug candidate VK2809. Viking is planning a Phase 2 clinical trial of VK2809 for the…

A study recently published in the journal Stem Cell Reports revealed a new method to significantly reduce the time necessary to reprogram and genetically correct stem cells to be used in therapeutic regenerative medicine, including for mitochondrial diseases. The study is entitled “Simultaneous Reprogramming…

DeuteRx LLC, a Boston-based biotechnology company dedicated to the improvement of marketed and candidate drugs, recently announced it will give an oral presentation on its candidate product DRX-065 at the ongoing American Association for the Study of Liver Diseases (AASLD) Annual Meeting. The presentation, entitled “DRX-065, the stabilized R-enantiomer…

Poxel SA, a biopharmaceutical company dedicated to novel treatments for type 2 diabetes, recently announced in a press release that its presentation at the 6th World Congress on Targeting Mitochondria in Berlin, Germany, Oct. 28–30, 2015, entitled “Imeglimin, a New Mitochondria Targeted Agent for Type 2 Diabetes…

Poxel SA, a biopharmaceutical company dedicated to novel treatments for type 2 diabetes, recently announced the presentation of preclinical data on Imeglimin, the company’s first-in-class lead anti-diabetic product, at the 6th World Congress on Targeting Mitochondria held in Berlin, Germany, Oct. 28–30, 2015. Imeglimin, an oral therapeutic agent…